Juvenile Xanthogranuloma clinical trials at UCSF
1 research study open to eligible people
Juvenile xanthogranuloma is a skin condition seen in children. UCSF is running trials to find new treatments for young patients with tough-to-treat cancers and histiocytic disorders. These trials use genetic tests to guide therapy choices.
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
open to eligible people ages 12 months to 21 years
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Oakland, California and other locations
Our lead scientists for Juvenile Xanthogranuloma research studies include Arun A. Rangaswami Jennifer G. Michlitsch.
Last updated: